BPC-157 / TB500 Blend

Name: BPC-157 / TB500 Blend
Availability: InStock

20mg vial (BPC-157 10mg + TB500 10mg)

A combined vial of BPC-157 and TB500 (Thymosin Beta-4 fragment) at a 1:1 ratio. The two peptides are frequently stacked in research protocols to target overlapping but distinct repair pathways - BPC-157 driving local cytoprotection and angiogenesis, TB500 driving systemic cell migration and actin remodelling. The blend simplifies dosing logistics for combined recovery work.

Select size

Checking availability…

Researched for

Dual-pathway acceleration of tendon, ligament and muscle recovery
Combined local cytoprotection and systemic repair-cell recruitment
Enhanced angiogenesis and microvascular remodelling at injury sites
Anti-inflammatory effects across NF-κB, TNF-α and IL-1β axes
Single-injection convenience for stacked recovery protocols
Frequently cited synergy in connective-tissue and post-surgical research

Mechanism of action

BPC-157 acts via the NO system, VEGF/EGF growth-factor signalling and FAK-paxillin pathway activation. TB500 sequesters G-actin monomers to drive cell migration, angiogenesis and progenitor recruitment. Together they target both the local injury site (BPC-157) and systemic repair cell mobilisation (TB500).

Research protocol

Common research protocols use 250–500mcg of each peptide once daily, or split into a morning/evening dose, subcutaneously near the site of interest. Cycles typically run 4–8 weeks on / 4 weeks off.

Half-life

BPC-157: approx. 4 hours. TB500: approx. 30–80 minutes plasma, with multi-day functional depot effect post SC/IM.

Reconstitution

Reconstitute a 20mg blend vial (10mg BPC-157 + 10mg TB500) with 3mL bacteriostatic water, or a 30mg blend vial (15mg BPC-157 + 15mg TB500) with 3mL BW for a 10mg/mL combined concentration (5mg/mL of each). Swirl gently - do not shake.

Storage

Lyophilised: 2–8°C, stable up to 24 months; avoid freeze-thaw cycles. Reconstituted: 2–8°C, protect from light, use within 30 days.

Research considerations

• Inherits the angiogenesis-related precaution of both parent peptides - avoid with active malignancy.
• Transient post-injection 'head rush' or mild fatigue may occur from the TB500 component.
• Direct combination-blend human data is limited; outcomes are extrapolated from single-peptide research.